WIF1, an inhibitor of the Wnt pathway, is rearranged in salivary gland tumors

Genes Chromosomes and Cancer

Volumn 46, Issue 3, 2007, Pages 215-225

  Queimado, Lurdes ^a   Lopes, Carla S ^b   Reis, Antonio H C ^c  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN WIFI; UNCLASSIFIED DRUG; WNT PROTEIN;

ALLELE; ARTICLE; BENIGN TUMOR; CANCER GENETICS; CANCER RESEARCH; CANCER SCREENING; CARCINOGENESIS; CHROMOSOME 12Q; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE FUSION; GENE IDENTIFICATION; GENE TARGETING; HMGA2 GENE; HUMAN; HUMAN TISSUE; MALIGNANT NEOPLASTIC DISEASE; NUCLEOTIDE SEQUENCE; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; SALIVARY GLAND TUMOR; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UPREGULATION; WIFI GENE; WILD TYPE;

ADENOMA, PLEOMORPHIC; ALLELES; CARCINOMA, ADENOID CYSTIC; CARCINOMA, MUCOEPIDERMOID; CARRIER PROTEINS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 12; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HUMANS; MYOEPITHELIOMA; ONCOGENE PROTEINS, FUSION; REPRESSOR PROTEINS; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; SIGNAL TRANSDUCTION; WNT PROTEINS;

MUS MUSCULUS;

EID: 33846512789     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20402     Document Type: Article

References (69)

1. Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD. 2006. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 27:1341-1348.
2. Arlotta P, Tai AK-F, Manfioletti G, Clifford C, Jay G, Ono SJ. 2000. Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J Biol Chem 275:14394-14400.
3. Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC, Chada K. 1995. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82:57-65.
4. Ashar HR, Tkachenko A, Shah P, Chada K. 2003. HMGA2 is expressed in an allele-specific manner in human lipomas. Cancer Genet Cytogenet 143:160-168.
5. Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, Santoro M, Croce CM, Fusco A. 1999. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 59:4793-4797.
6. Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O, Myklebost O. 1997. HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. Oncogene 14:2935-2941.
7. Bierie B, Nozawa M, Renou JP, Shillingford JM, Morgan F, Oka T, Taketo MM, Cardiff RD, Miyoshi K, Wagner KU, Robinson GW, Hennighausen L. 2003. Activation of β-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 22:3875-3887.
8. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. 1999. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 59:3866-3869.
9. Cavazzoni A, Petronini PG, Galetti M, Roz L, Andriani F, Carbognani P, Rusca M, Fumarola C, Alfieri R, Sozzi G. 2004. Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line. Oncogene 23:8439-8446.
10. Cebrat M, Strzadala L, Kisielow P. 2004. Wnt inhibitory factor-1: A candidate for a new player in tumorigenesis of intestinal epithelial cells. Cancer Lett 206:107-113.
11. El-Naggar AK, Callender D, Coombes MM, Hurr K, Luna MA, Batsakis JG. 2000. Molecular genetic alterations in carcinoma expleomorphic adenoma: A putative progression model? Genes Chromosomes Cancer 27:162-168.
12. El-Naggar AK, Hurr K, Kagan J, Gillenwater A, Callender D, Luna MA, Batsakis JG. 1997. Genotypic alterations in benign and malignant salivary gland tumors: Histogenetic and clinical implications. Am J Surg Pathol 21:691-697.
13. Eveson JW, Yeudal A. 2001. What is the evidence for the progression from benign to malignant pleomorphic adenoma? In: McGurk M, Renehan A, editors. Controversies in the Management of Salivary Gland Disease. Oxford, NY: Oxford University Press, pp. 105-113.
14. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E, Santoro M, Croce CM, Fusco A. 2002. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21:3190-3198.
15. Fedele M, Berlingieri MT, Scala S, Chiariotti L, Viglietto G, Rippel V, Bullerdiek J, Santoro M, Fusco A. 1998. Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene 17:413-418.
16. Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C, Melillo RM, Helin K, Croce CM, Fusco A. 2006. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 9:459-471.
17. Fejzo MS, Yoon SJ, Montgomery KT, Rein MS, Weremowicz S, Krauter KS, Dorman TE, Fletcher JA, Mao JI, Moir DT, Kucherlapati RS, Morton CC. 1995. Identification of a YAC spanning the translocation breakpoints in uterine leiomyomata, pulmonary chondroid hamartoma, and lipoma: Physical mapping of the 12q14-q15 breakpoint region in uterine leiomyomata. Genomics 26:265-271.
18. Geurts JM, Schoenmakers EF, Roijer E, Astrom AK, Stenman G, van de Ven WJ. 1998. Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene 16:865-872.
19. Geurts JM, Schoenmakers EF, Roijer E, Stenman G, Van de Ven WJ. 1997. Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Cancer Res 57:13-17.
20. Gillenwater A, Hurr K, Wolf P, Batsakis JG, Goepfert H, El-Naggar AK. 1997. Microsatellite alterations at chromosome 8q loci in pleomorphic adenoma. Otolaryngol Head Neck Surg 117: 448-452.
21. Hisaoka M, Sheng WQ, Tanaka A, Hashimoto H. 2002. HMGIC alterations in smooth muscle tumors of soft tissues and other sites. Cancer Genet Cytogenet 138:50-55.
22. Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J. 1999. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398:431-436.
23. Hunter DD, Zhang M, Ferguson JW, Koch M, Brunken WJ. 2004. The extracellular matrix component WIF-1 is expressed during, and can modulate, retinal development. Mol Cell Neurosci 27:477-488.
24. Johns MM, Westra WH, Califano JA, Eisele D, Koch WM, Sidransky D. 1996. Allelotype of salivary gland tumors. Cancer Res 56:1151-1154.
25. Kawano Y, Kypta R. 2003. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116:2627-2634.
26. Knudson AG, Jr. 1971. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
27. Kurose K, Mine N, Iida A, Nagai H, Harada H, Araki T, Emi M. 2001. Three aberrant splicing variants of the HMGIC gene transcribed in uterine leiomyomas. Genes Chromosomes Cancer 30:212-217.
28. Y, Podsypanina K, Liu X, Crane A, Tan L, Parsons R, Varmus H. 2001. Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol 2:2.
29. Lustig B, Behrens J. 2003. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129:199-221.
30. Luu H, Zagaja G, Dubauskas Z, Chen S, Smith R, Watabe K, Ichikawa Y, Ichikawa T, Davis E, Le Beau M, Rinker-Schaeffer C. 1998. Identification of a novel metastasis-suppressor region on human chromosome 12. Cancer Res 58:3561-3565.
31. Mark J, Dahlenfors R, Wedell B. 1997. Impact of the in vitro technique used on the cytogenetic patterns in pleomorphic adenomas. Cancer Genet Cytogenet 95:9-15.
32. Martins C, Fonseca I, Felix A, Roque L, Soares J. 1995. Benign salivary gland tumors: A cytogenetic study of 21 cases. J Surg Oncol 60:232-237.
33. Martins C, Fonseca I, Roque L, Pinto AE, Soares J. 1996. Malignant salivary gland neoplasms: A cytogenetic study of 19 cases. Eur J Cancer B Oral Oncol 2:128-132.
34. Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM. 2004. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64:4717-4720.
35. Meza-Zepeda LA, Berner JM, Henriksen J, South AP, Pedeutour F, Dahlberg AB, Godager LH, Nizetic D, Forus A, Myklebost O. 2001. Ectopic sequences from truncated HMGIC in liposarcomas are derived from various amplified chromosomal regions. Genes Chromosomes Cancer 31:264-273.
36. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. 2004. WNT and β-catenin signalling: Diseases and therapies. Nat Rev Genet 5:691-701.
37. Mullenbach R, Lagoda PJ, Welter C. 1989. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 5:391.
38. Nelson WJ, Nusse R. 2004. Convergence of Wnt, β-catenin, and cadherin pathways. Science 303:1483-1487.
39. Olsen KD, Lewis JE. 2001. Carcinoma ex pleomorphic adenoma: A clinicopathologic review. Head Neck 23:705-712.
40. Petit M, Mols R, Schoenmakers EF, Mandahl N, Van de Ven WJ. 1996. LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family. Genomics 36:118-129.
41. Poetsch M, Zimmermann A, Wolf E, Kleist B. 2005. Loss of heterozygosity occurs predominantly, but not exclusively, in the epithelial compartment of pleomorphic adenoma. Neoplasia 7:688-695.
42. Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, Dal Cin P, Morton CC. 2003. Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Cancer Res 63:1351-1358.
43. Queimado L, Lopes C, Du F, Martins C, Fonseca I, Bowcock AM, Soares J, Lovett M. 1999. In vitro transformation of cell lines from human salivary gland tumors. Int J Cancer 81:793-798.
44. Queimado L, Seruca R, Costa-Pereira A, Castedo S. 1995. Identification of two distinct regions of deletion at 6q in gastric carcinoma. Genes Chromosomes Cancer 14:28-34.
45. Reguart N, He B, Xu Z, You L, Lee AY, Mazieres J, Mikami I, Batra S, Rosell R, McCormick F, Jablons DM. 2004. Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem Biophys Res Commun 323:229-234.
46. Reya T, Clevers H. 2005. Wnt signalling in stem cells and cancer. Nature 434:843-850.
47. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, Bullerdiek J. 1996. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 149:775-779.
48. Roijer E, Kas K, Behrendt M, Van de Ven W, Stenman G. 1999. Fluorescence in situ hybridization mapping of breakpoints in pleomorphic adenomas with 8q12-13 abnormalities identifies a subgroup of tumors without PLAG1 involvement. Genes Chromosomes Cancer 24:78-82.
49. Roijer E, Nordkvist A, Strom AK, Ryd W, Behrendt M, Bullerdiek J, Mark J, Stenman G. 2002. Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma. Am J Pathol 160:433-440.
50. Roose J, Huls G, van Beest M, Moerer R van der Horn K, Goldschmeding R, Logtenberg T, Clevers H. 1999. Synergy between tumor suppressor APC and the β-catenin-Tcf4 target Tcf1. Science 285:1923-1926.
51. Roulet E, Armentero MT, Krey G, Corthesy B, Dreyer C, Mermod N, Wahli VV. 1995. Regulation of the DNA-binding and transcriptional activities of Xenopus laevis NFI-X by a novel C-terminal domain. Mol Cell Biol 15:5552-5562.
52. Rubin JS, Barshishat-Kupper M, Feroze-Merzoug F, Xi ZF. 2006. Secreted WNT antagonists as tumor suppressors: Pro and con. Front Biosci 11:2093-2105.
53. Sambrook J, Russell DW. 2001. Molecular Cloning: A Laboratory-Manual, 3rd ed. New York: Cold Spring Harbor Laboratory.
54. Schoenberg Fejzo M, Ashar HR, Krauter KS, Powell WL, Rein MS, Weremowicz S, Yoon SJ, Kucherlapati RS, Chada K, Morton CC. 1996. Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that in lipomas. Genes Chromosomes Cancer 17:1-6.
55. Schoenmakers EF, Huysmans C, Van de Ven WJ. 1999. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. Cancer Res 59:19-23.
56. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. 1995. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 10:436-444.
57. Seifert G, Brocheriou C, Cardesa A, Eveson JW. 1990. WHO international histological classification of tumours. Tentative histological classification of salivary gland tumours. Pathol Res Pract 186: 555-581.
58. Speight PM, Barrett AW. 2002. Salivary gland tumours. Oral Dis 8:229-240.
59. Steele-Perkins G, Plachez C, Butz KG, Yang G, Bachurski CJ, Kinsman SL, Litwack ED, Richards LJ, Gronostajski RM. 2005. The transcription factor gene Nfib is essential for both lung maturation and brain development. Mol Cell Biol 25:685-698.
60. Stepanova L, Finegold M, DeMayo F, Schmidt EV, Harper JW. 2000. The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. Mol Cell Biol 20:4462-4473.
61. Stern C, Meyer K, Bartnitzke S, Schloot W, Bullerdiek J. 1990. Pleomorphic adenomas with unbalanced chromosomal abnormalities have an increased in vitro lifetime. Cancer Genet Cytogenet 46:55-63.
62. Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K, Shinomura Y. 2005. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24:7946-7952.
63. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. 1988. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55:619-625.
64. Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li LC, Ribeiro-Filho LA, Terashima M, Kikuno N, Adachi H, Yoneda T, Kishi H, Shigeno K, Konety BR, Igawa M, Dahiya R. 2006. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/β-catenin signaling pathway. Clin Cancer Res 12: 383-391.
65. Van de Ven WJ, Schoenmakers EF, Wanschura S, Kazmierczak B, Kools PF, Geurts JM, Bartnitzke S, Van den Berghe H, Bullerdiek J. 1995. Molecular characterization of MAR, a multiple aberration region on human chromosome segment 12q13-q15 implicated in various solid tumors. Genes Chromosomes Cancer 12:296-303.
66. Wanschura S, Dal Cin P, Kazmierczak B, Barnitzke S, Van den Berghe H, Bullerdiek J. 1997. Hidden paracentric inversions of chromosome arm 12q affecting the HMGIC gene. Genes Chromosomes Cancer 18:322-323.
67. Wanschura S, Kazmierczak B, Schoenmakers E, Meyen E, Bartnitzke S, Van de Ven W, Bullerdiek J, Schloor W. 1995. Regional fine mapping of the multiple-aberration region involved in uterine leiomyoma, lipoma, and pleomorphic adenoma of the salivary gland to 12q15. Genes Chromosomes Cancer 14:68-70.
68. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A, Pilarsky C. 2003. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201:204-212.
69. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, Rudiger T, McCue PA, Croce CM, Huebner K. 2001. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 98:10250-10255.